These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33972053)

  • 1. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
    Patsatsi A; Kyriakou A
    Clin Dermatol; 2021; 39(1):52-55. PubMed ID: 33972053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic drugs during COVID-19 outbreak.
    Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
    Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
    [No Abstract]   [Full Text] [Related]  

  • 3. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
    Yim RM; Singh I; Armstrong AW
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Practical Guide to Using Biologics in Pediatric Dermatology.
    George A; Lansang RP; Lansang P; Gooderham M
    J Cutan Med Surg; 2024; 28(1):59-67. PubMed ID: 38229411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].
    Zimman S; Cura MJ; Luna PC; Echeverría CM; Mazzuoccolo LD
    Actas Dermosifiliogr (Engl Ed); 2020 Nov; 111(9):806-807. PubMed ID: 32576376
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunobiologicals in dermatology.
    Silva DLFD; Secamilli EN; Beleli MV; Massuda JY; Franca AFEC; Magalhães RF
    An Bras Dermatol; 2022; 97(3):275-283. PubMed ID: 35314083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What's New in Dermatological Therapy?].
    Bachelez H
    Ann Dermatol Venereol; 2015 Dec; 142 Suppl 3():S49-54. PubMed ID: 26792414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
    Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
    Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
    Lee BR; Brostek AR; Kaffenberger BH
    J Am Acad Dermatol; 2024 Jul; 91(1):100-102. PubMed ID: 38490372
    [No Abstract]   [Full Text] [Related]  

  • 10. Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
    Rosi E; Pimpinelli N; Prignano F
    J Dermatolog Treat; 2022 Feb; 33(1):599. PubMed ID: 32432955
    [No Abstract]   [Full Text] [Related]  

  • 11. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.
    Torres T; Puig L
    Am J Clin Dermatol; 2020 Jun; 21(3):307-311. PubMed ID: 32277351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Biologics During the COVID-19 Pandemic.
    Jones ME; Kucharik AH; Pourali SP; Rajkumar JR; Gutierrez Y; Yim RM; Armstrong AW
    Dermatol Clin; 2021 Oct; 39(4):545-553. PubMed ID: 34556244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapy.
    Aguwa C; Enwereji N; Santiago S; Hine A; Kels GG; McGee J; Lu J
    Clin Dermatol; 2023; 41(5):640-649. PubMed ID: 37816413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remote management of hidradenitis suppurativa in a pandemic era of COVID-19.
    Kang NC; Hsiao J; Shi V; Naik HB; Lowes MA; Alavi A
    Int J Dermatol; 2020 Sep; 59(9):e318-e320. PubMed ID: 32578210
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.
    Campanati A; Diotallevi F; Martina E; Radi G; Offidani A
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for chronic inflammatory skin diseases: an update for the clinician.
    Yao Y; Ravn Jørgensen AH; Thomsen SF
    J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.
    Campione E; Lanna C; Diluvio L; Cannizzaro MV; Grelli S; Galluzzo M; Talamonti M; Annicchiarico-Petruzzelli M; Mancini M; Melino G; Candi E; Schiavone G; Wang Y; Shi Y; Bianchi L
    Cell Cycle; 2020 Feb; 19(3):257-267. PubMed ID: 31905036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Microbiome: Composition and Role in Inflammatory Skin Diseases.
    Balato A; Cacciapuoti S; Di Caprio R; Marasca C; Masarà A; Raimondo A; Fabbrocini G
    Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):1-18. PubMed ID: 30302512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules.
    Costello C; Maarouf M; Shi V
    J Drugs Dermatol; 2018 Dec; 17(12):1330-1332. PubMed ID: 30586268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.